In addition, it has been found that CD4+FoxP3-PD-1hi T cells (4PD-1hi) accumulate intratumorally in NSCLC patients and that a lack of effective 4PD-1hi reduction after anti-PD-1 therapy correlates with poor prognosis [53]. Here, FOXP3 is linked to non-small cell lung carcinoma.